Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|September 22, 2017

MilliporeSigma Opens First Biodevelopment Center in China

MilliporeSigma announced the opening of its first end-to-end biodevelopment center in the Asia Pacific (APAC) region.

On Sept. 21, 2017, MilliporeSigma, the life-science subsidiary of Merck KGaA, announced the opening of its first end-to-end biodevelopment center in the Asia Pacific (APAC) region. The center, located in Shanghai, China, will provide a range of process development capabilities and services, including upstream and downstream process development, non-GMP clinical production, and cell line development.

The facility will also provide an integrated suite of services for biopharmaceutical companies across APAC to facilitate clinical drug development from molecule to commercial production. Following the opening of the Martillac, France site in 2012, the development of the Shanghai center is part of company efforts announced in January 2017 to expand its global reach, with a center in Burlington, MA still in development.

Source: MilliporeSigma


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.